ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 069,33
-0,28%
Dow Jones
38 460,92
-0,11%
DAX
18 008,32
-0,36%
Brent Oil
87,405
0,21%
Bitcoin
64 039,92
-0,38%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. AbbVie Inc (ABBV)

  7. AbbVie Inc (ABBV) Actualités

ABBV AbbVie Inc

167,80
0,00 (0,00%)
25 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
AbbVie Inc ABBV NYSE Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 167,80 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
167,80
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
23/4/202414:00PRNUSAllergan Aesthetics Invites Consumers to Be the Face of..
18/4/202414:31PRNUSPhase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed..
12/4/202413:30PRNUSAbbVie Announces Late-Breaking Data at AAN Supporting..
09/4/202414:00PRNUSSkinMedica® Empowers Clear Skin Confidence with a New,..
04/4/202414:00PRNUSAbbVie to Host First-Quarter 2024 Earnings Conference Call
03/4/202414:30PRNUSAllergan Aesthetics Announces the Return of CoolMonth with..
01/4/202413:50GLOBENEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an..
26/3/202412:20IHMARKETNEWSSuper Micro Computer and Seagate Shares Surge on Analyst..
25/3/202416:00PRNUSAllergan Aesthetics Launches "Moving the Needle on Ethics"..
25/3/202413:31PRNUSAbbVie to Acquire Landos Biopharma, Further Strengthening..
25/3/202413:30GLOBEAbbVie to Acquire Landos Biopharma, Further Strengthening..
22/3/202420:02PRNUSU.S. Food and Drug Administration (FDA) Grants Full Approval..
21/3/202413:00PRNUSALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY,..
07/3/202414:00PRNUSAbbVie to Present at the Barclays 26th Annual Global..
06/3/202414:03PRNUSAbbVie and Allergan Aesthetics to Present New Data at 2024..
05/3/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202418:09PRNCADragonfly a reçu un paiement d'étape à la suite de la prise..
05/3/202414:00PRNUSJUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA..
05/3/202413:00PRNCADragonfly has Received Milestone Payment Following Dosing of..
02/3/202401:53EDGAR2Form 144 - Report of proposed sale of securities
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202422:20EDGAR2Form 144 - Report of proposed sale of securities
01/3/202400:06EDGAR2Form 144 - Report of proposed sale of securities
29/2/202423:33EDGAR2Form 144 - Report of proposed sale of securities
29/2/202422:04EDGAR2Form 144 - Report of proposed sale of securities
28/2/202406:05PRNUSAbbVie and OSE Immunotherapeutics Announce Partnership to..
27/2/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202414:00GLOBEHealis Therapeutics' asset CKDB-501A shares Phase III..
27/2/202413:45PRNUSU.S. Food and Drug Administration (FDA) Grants Priority..
26/2/202423:08EDGAR2Form 8-K - Current report
26/2/202412:12EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202422:04EDGAR2Form 144 - Report of proposed sale of securities
22/2/202414:05PRNUSAbbVie and Tentarix Announce Collaboration to Develop..
22/2/202400:00EDGAR2Form 144 - Report of proposed sale of securities
21/2/202414:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
21/2/202414:00PRNUSBOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024..
20/2/202423:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202423:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202423:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NYSE
ABBV
AbbVie
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés